Floatz logo

Defibrotide

Sickle Cell Disease

New York Medical Collegenucleic_acidPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

134 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Defibrotide is also rated in:

acute chest syndromeDormant
B
Indicative ·
57 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
toxic encephalopathyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →